Investigational drug · Phase 2
JDB0131
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "JDB0131"
First trial start
2025
Sep 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JDB0131", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tuberculosis
- Multidrug Resistant Pulmonary Tuberculosis
- Rifampicin-resistant Tuberculosis
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "JDB0131" as an intervention, largest first.
WestVac Biopharma Co., Ltd.Industry
NCT07170800 · 60 participants (planned) · Start Sep 19, 2025 · Primary completion Feb 28, 2026
Drug: JDB0131 100mg; JDB0131 200mg and 1 more · For: Tuberculosis; Multidrug Resistant Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
Sites: Wuhan, China; Changsha, China; Nanjing, China · 7 sites in all
- Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary TuberculosisStatus unknown
Beijing Chest HospitalAcademic, hospital or other
NCT06224036 · 52 participants (planned) · Start Oct 31, 2023 · Primary completion Mar 31, 2024
Drug: JDB0131; Delamanid and 1 more · For: Drug-resistant Tuberculosis
Sites: Wuhan, China; Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial.
Chu N, Nie W, Du J, et al. · Signal Transduct Target Ther 2025
Also in development for Tuberculosis
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- MTBVACBBV169Phase 32 trials
Biofabri, S.L · Tuberculosis, Tuberculosis (TB)
- TB-PPDPurified Protein Derivative of TuberculinPhase 32 trials
Chengdu CoenBiotech Co., Ltd · Tuberculosis, Latent Tuberculosis Infection
- DelamanidPhase 22 trials
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- BNT164a1Phase 21 trial
BioNTech SE · Tuberculosis
- BNT164b1Phase 21 trial
BioNTech SE · Tuberculosis
- BTZ-043Phase 21 trial
GSK · Tuberculosis
- GSK3036656Phase 21 trial
GSK · Tuberculosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.